Please provide your email address to receive an email when new articles are posted on . Patients with HER2-positive metastatic breast cancer had a real-world PFS of 1 year on trastuzumab deruxtecan.

The study results “highlight how even well-intentioned efforts to save patients’ time may face barriers,” the researchers wrote.

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% ...